FRONTAGE (01521) surged nearly 10%, and as of press time, the stock was up 9.02% to HK$1.45, with a trading volume of HK$1.925 million. On the news front, FRONTAGE announced its interim results for the six months ended June 30, 2025. The group recorded revenue of US$127 million during the period, down 1.5% year-on-year. Profit attributable to owners of the company reached US$2.927 million, representing a turnaround from losses in the previous year. Basic earnings per share were US$0.0014. Among the highlights, the group recorded losses in the first quarter of 2025. However, benefiting from increased market demand and biopharmaceutical companies increasing outsourcing services to reduce costs, the group's second-quarter financial performance rebounded, recording revenue of approximately US$69.5 million, up 7.8% year-on-year, and net profit of approximately US$3.8 million.